(ek oh THYE oh fate EYE oh dide)
- Ecostigmine Iodide
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Reconstituted, Ophthalmic:
Phospholine Iodide: 0.125% (5 mL)
Brand Names: U.S.
- Phospholine Iodide
- Acetylcholinesterase Inhibitor
- Ophthalmic Agent, Antiglaucoma
- Ophthalmic Agent, Miotic
Long-acting inhibition of cholinesterase enhances activity of endogenous acetylcholine. Reduced degradation of acetylcholine leads to continuous stimulation of the ciliary muscle producing miosis; other effects include potentiation of accommodation and facilitation of aqueous humor outflow, with attendant reduction in intraocular pressure.
Onset of Action
Miosis: ≤60 minutes; Peak effect: Intraocular pressure decrease: 24 hours
Duration of Action
Miosis: 1 to 4 weeks; Intraocular pressure: Days to weeks.
Use: Labeled Indications
Accommodative esotropia: Concomitant esotropias with a significant accommodative component.
Glaucoma: Treatment of chronic open-angle glaucoma; subacute or chronic angle-closure glaucoma (postiridectomy or where surgery is refused or contraindicated); certain nonuveitic secondary types of glaucoma, especially glaucoma following cataract surgery.
Hypersensitivity to echothiophate or any component of the formulation; most cases of angle-closure glaucoma; active uveal inflammation
Children and Adolescents: Accommodative esotropia:
Diagnosis: Instill 1 drop (0.125%) once daily into both eyes at bedtime for 2 to 3 weeks
Treatment: Usual dose: Instill 1 drop of 0.06% once daily or 0.125% every other day (maximum: 1 drop of 0.125% in both eyes/day). Note: Use lowest concentration and frequency which gives satisfactory response; 0.3% has been proven to be effective.
Initial: Instill 1 drop (0.03%) twice daily into eyes with 1 dose just prior to bedtime
Maintenance: Twice-daily dosing is preferred, but some patients have been treated with once-daily or every-other-day dosing (with 1 dose just prior to bedtime).
Conversion from other ophthalmic agents: If IOP control was unsatisfactory, patients may require higher doses of echothiophate (eg, ≥0.06%); however, patients should be initially started on the 0.03% strength for a short period to better tolerance.
Dosage adjustment in renal impairment: There are no dosage adjustments provided in the manufacturer's labeling.
Dosage adjustment in hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling.
Pour diluent into drug container; without compressing rubber bulb, insert dropper assembly into drug container and screw down tightly. Shake well to ensure mixing.
Proper administration technique is required for maximal benefit. The nasolacrimal duct(s) should be compressed for 1 to 2 minutes after instillation of the drops. Excess fluid around the eye should be blotted with tissue; wash hands after instillation.
Store undiluted vials at 2°C to 8°C (36°F to 46°F). Store reconstituted solutions at ~25°C (~77°F); do not refrigerate; discard unused solution after 4 weeks.
Cyclopentolate: May diminish the therapeutic effect of Echothiophate Iodide. Monitor therapy
Succinylcholine: Echothiophate Iodide may increase the serum concentration of Succinylcholine. Management: For patients receiving echothiophate iodide eye drops, consider using a neuromuscular-blocking agents other than succinylcholine. If succinylcholine is used, consider a reduced dose, and monitor for enhanced/prolonged effects. Consider therapy modification
Frequency not defined.
Cardiovascular: Bradycardia, cardiac irregularities, flushing, hypotension
Gastrointestinal: Diarrhea, nausea, vomiting
Neurologic & skeletal: Muscle weakness
Ocular: Blurred vision, browache, burning eyes, ciliary redness, conjunctival redness/thickening, intraocular pressure increases (paradoxical), iris cysts, lacrimation, lid muscle twitching, miosis, myopia, latent iritis or uveitis activation, lens opacities, retinal detachment, stinging
Miscellaneous: Diaphoresis, nasolacrimal canal obstruction
Concerns related to adverse effects:
• Cardiac irregularities: Temporarily or permanently discontinue if cardiac irregularities occur.
• Cholinergic effects: Discontinue if symptoms of excess cholinergic activity (eg, salivation, sweating, urinary incontinence); overdosage may result in cholinergic crisis, which must be distinguished from myasthenic crisis.
• Asthma: Not generally recommended for use in patients with asthma.
• Cardiovascular disease: Not generally recommended for use in patients with bradycardia, hypotension or recent MI.
• Gastrointestinal disease: Not generally recommended for use in patients with spastic gastrointestinal disturbances or peptic ulcer disease.
• Parkinsonism: Not generally recommended for use in patients with Parkinsonism.
• Seizure disorder: Not generally recommended for use in patients with a history of seizure disorder.
• Vagotonia: Not generally recommended for use in patients with vagotonia.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Appropriate use: Do not use for tonometric glaucoma, or in patients with active or history of uveitis, or history of retinal detachment. Use cautiously prior to ophthalmic surgery due to risk of blood in the anterior chamber. Compress the nasolacrimal ducts for 1 to 2 minutes following instillation to minimize drainage into the nasal chamber. Wash hands following instillation.
• Exposure to pesticides and insecticides: Use with caution in patients exposed to carbamate- or organophosphate-type insecticides and pesticides; absorption of the pesticide through skin or respiratory tract may result in additive systemic effects; respiratory masks and frequent clothing changes may be necessary during exposure to pesticides in patients receiving echothiophate iodide.
• Tolerance: Patients may develop tolerance after prolonged use; a rest period restores response to the drug.
Baseline measurement of anterior chamber angle; routine lens examinations (for opacities and during treatment of accommodative esotropia); IOP (at different times of the day)
Pregnancy Risk Factor
Animal reproduction studies have not been conducted.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience lacrimation. Have patient report immediately to prescriber vision changes, ophthalmalgia, severe eye irritation, tachycardia, bradycardia, arrhythmia, diarrhea, difficult urination, sialorrhea, asthenia, hyperhydrosis, or dyspnea (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
More about echothiophate iodide ophthalmic
- Other brands: Phospholine Iodide